Focused on delivering

Oxford BioMedica annual report and accounts 2016

Our sixth annual report for Oxford BioMedica continues to be one of the very best documents in the sector. It's an exciting time for the OXB as they develop their own gene and cell therapy products, and also partner with others to deliver novel treatments such as CTL019 by Norvartis, a late stage product targeting blood cancer that uses Oxford BioMedica's LentiVector delivery technology.

The 2016 report tells the story of how Oxford BioMedica and the gene and cell therapy sector are now delivering.

annual reports / investor communication materials